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INTRODUCTION
The CLA story began with the discovery by Pariza and co-workers that fat extract
from ruminants contained compounds that possessed anticarcinogenic activity. They
subsequently identified these compounds as conjugated dienoic isomers of linoleic acid
and coined the term conjugated linoleic acid or CLA (see review 1). Over the last
decade the published research on the biology of CLA has increased exponentially and
many additional health benefits have been identified (Table 1; 2). The range of
physiological processes affected by CLA is impressive and raises interesting questions
as to mechanisms.
Table 1.

Beneficial health effects of CLA reported from biomedical
studies with animal modelsa.
Biological effect
Anticarcinogenic effects (in vivo and in vitro studies)
Antiatherogenic properties
Altered nutrient partitioning and lipid metabolism
Antidiabetic (type II diabetes) and reduced hyperglycemia
Immune modulation
Improved bone mineralization
a
Adapted from Bauman et al. (3).
The CLA in human diets originate almost exclusively from food products of
ruminant origin and we presented our first paper on CLA at this conference in 1996 (4).
Our interest related to identifying micro-nutrients that provide a beneficial health effect in
foods beyond their traditional nutritional value. This concept is often referred to as
“functional foods” and offers the potential to design foods in ways that improve their
healthfulness. In general, the physiological effects of CLA have been identified using
biomedical studies with animal models and chemically synthesized CLA supplements
that contain a variety of isomers. Many CLA isomers are possible and they can differ in
both the position of the conjugated double bonds (e.g. 8-10, 9-11, 10-12, etc.) and the
configuration of the double bonds (cis-cis, cis-trans, trans-cis, or trans-trans). The
predominant isomer in milk and beef fat is cis-9, trans-11 CLA, but sophisticated
analytical techniques have revealed that ruminant fat contains minor or trace amounts
of over 20 CLA isomers (5). Thus, it is of obvious interest to establish the relationship of
specific isomers to the various biological effects observed when commercial
supplements of CLA are fed. It is clear that the cis-9, trans-11 CLA isomer possesses
anticarcinogenic activity. Of special significance are our recent studies showing that
this isomer is also effective when consumed as a natural component of foods – in this
case we used a rat model for breast cancer and included a dietary supplement of butter
that had been naturally enriched in cis-9, trans-11 CLA (6). The trans-10, cis-12 CLA
isomer has a clear effect on lipid metabolism thereby reducing milk fat synthesis in
lactating animals and body fat accretion in growing animals (see review 7). In addition,
our recent work suggests that the trans-10, cis-12 isomer is responsible for the anti
diabetic effects (8).
Understanding the biology of specific CLA isomers continues to be an area of
active research. From the perspective of ruminants, the focus has been on two CLA

isomers – cis-9, trans-11 and trans-10, cis-12. Enhancing ruminant fat content of the
former is of interest because of the demonstrated role of cis-9, trans-11 CLA as an
anticarcinogen, whereas trans-10, cis-12 CLA is of interest because of its effects on
lipid metabolism. In the following sections we will summarize recent developments
related to these two CLA isomers. For more comprehensive summaries of the ruminant
dimension of CLA we refer readers to recent reviews (3, 9, 10).
CIS-9, TRANS-11 CLA AND MILK FAT
The uniqueness of ruminant-derived foods as a source of CLA relates to rumen
biohydrogenation. CLA is an intermediate in the rumen biohydrogenation of linoleic acid
and it had been assumed this was the sole source of the CLA found in milk and beef fat.
However, Griinari and Bauman (9) challenged this based on the kinetics of rumen
biohydrogenation and observations that dietary polyunsaturated fatty acids other than
linoleic also increased the CLA content of milk fat. We suggested an alternative source
could be endogenous synthesis involving the enzyme �9-desaturase. The substrate for
this reaction would be trans-11 C18:1, another intermediate formed in rumen
biohydrogenation. In a series of studies, we manipulated the supply of trans-11 C18:1
and altered the activity of �9-desaturase under different experimental conditions (11,
12). Overall, our results indicate that endogenous synthesis is the major source
accounting for over two-thirds of the CLA in milk fat (Table 2). Thus, considering rumen
production of trans-11 C18:1 is critical in attempts to increase the CLA content of milk
and beef fat.
Previous studies investigating dietary influences on CLA production have
demonstrated a wide range in CLA content of milk fat among individual cows on a given
diet (e.g. see 13-17). These observations combined with the data on the contribution of
endogenous synthesis to milk fat CLA discussed above, led us to investigate the
sources of variation in CLA production in dairy cows (18). Briefly, our study consisted of
three groups of animals (n = 10 per group); one maintained on a standard TMR, one
maintained on a diet that included extruded full-fat soybeans as a slow-release source
of linoleic acid designed to elevate milk fat CLA, and a third group that was switched
between these diets at 3 week intervals over the course of the 12 week study.
The diets gave the expected difference in CLA content of milk fat with the
extruded full-fat soybean diet averaging about twice that of cows fed the TMR diet.
Similar to previous studies we observed a 2- to 3-fold range in CLA concentration in
milk fat among individuals on each of the diets. A key observation was the remarkable
consistency in hierarchy of CLA content among cows over the 12 week period. The
consistency was similar for all 3 groups. We have included a graphic representation for
the treatment group that switched between the two diets at 3 week intervals because
the data illustrate that the rank order was maintained not only over time, but also across
dietary shifts (Figure 1). Also evident in this treatment group was a range in the
magnitude of response to dietary shifts among cows; some cows had a minimal
response to diet shifts while others increased milk fat content of CLA more than double.

Table 2. Importance of endogenous synthesis of cis-9, trans-11 CLA in milk fat.
Milk Fat CLA
Endogenous
in Control
Synthesis of
Diet
(mg/g fatty acid)
c9, t11 CLAa
Reference
Total mixed ration
Total mixed ration

4.2
6.5
7.6

64%
78%

Griinari et al. (11)

+ PHVOb

Corl et al. (12)

Pasture
15.5
71%
Kay et al. (unpublished)
Estimated by use of sterculic oil as a source of cyclopropene fatty acids to block
�9-desaturase.
b
Partially hydrogenated vegetable oil.
a
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Figure 1. Temporal pattern of the hierarchy in milk fat CLA for cows
alternated between high and standard CLA diets in successive
periods (3 wk intervals). Adapted from Kelsey et al. (18).
The second facet addressed in our investigation involved analyzing the variation
associated with endogenous synthesis of CLA and �9-desaturase. There are four main
indices that represent a proxy of desaturase activity and we refer to them as the
desaturase index. These are fatty acid pairs that represent a product:substrate ratio for
�9-desaturase, and they include the myristoleic ratio (C14:1/C14:0), the palmitoleic ratio
(C16:1/C16:0), the oleic ratio (C18:1/C18:0), and the CLA ratio (cis-9, trans-11 CLA/trans-11
C18:1). Of these four, the myristoleic ratio is of particular value because the only source
of myristic acid (substrate) is mammary de novo synthesis and therefore all myristoleic
acid present is a product of mammary �9-desaturase activity. All three of the other
indices are confounded by possible contribution from the diet and/or �9-desaturase
present in other tissues, and are therefore less rigorous in terms of indicating mammary
�9-desaturase activity. Results were similar for all three treatment groups and we have
presented data from the group that switched between diets as an illustration (Figure 2).
Again we observed a highly consistent hierarchy among individuals over time as well as
a similar 2- to 3-fold range across animals within each group. Our study demonstrates
that there is significant animal-to-animal variation in response to a CLA-enhancing diet
and in �9-desaturase activity, although individual animals remain quite consistent over
time and across diets (18). Thus, dietary manipulation of milk fat CLA acts in concert
with individual animal traits to culminate in the observed content of CLA in milk fat.
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Figure 2. Temporal pattern of the C 14:1/C14:0 desaturase index hierarchy
for cows alternated between a high and standard CLA diet in
successive periods (3 wk intervals). Adapted from Kelsey et al.
(18).
Advances in understanding the biology of CLA in ruminants have been sufficient
to allow formulation of strategies to increase the content of cis-9, trans-11 CLA in milk
fat. A schematic to illustrate potential strategies was developed by M. Griinari and it is
presented in Figure 3. Four key sites have been listed where intervention would
increase fat content of CLA. The first two involve alterations in the rumen that would
increase the rumen production of substrate for use in endogenous synthesis of CLA.
Increasing the supply of C18 polyunsaturated fatty acids would be beneficial (Figure 3,
#1) because the biohydrogenation of both linoleic acid and linolenic acid results in the
production of trans-11 C18:1 as an intermediate. At the same time, the outflow of trans
11 C18:1 from the rumen would be markedly enhanced if the terminal reductase step in
biohydrogenation is inhibited (Figure 3, #2). We have suggested that diet supplements
of fish oil increase milk fat content of CLA because they result in a less complete
biohydrogenation sequence through an inhibition of the reductase reaction (3). The
third site highlighted is to prevent an isomerase shift in rumen biohydrogenation (Figure
3).
This often occurs with the addition of oils and while the proportion of
biohydrogenation via an alternate pathway is minor, it has pronounced undesirable
effects. The trans-10, cis-12 CLA isomer causes a reduction in total milk fat and also
inhibits �9-desaturase, thereby reducing endogenous synthesis of cis-9, trans-11 CLA.
The final site listed is to enhance endogenous synthesis via effects on the activity or
gene expression of �9-desaturase (Figure 3). The regulation of �9-desaturase has been
extensively investigated using the enzyme from rodent liver and results show it is
affected by diet, hormonal balance and physiological state (3). Presently, several
groups are extending this work to ruminants and to the mammary enzyme.
Nevertheless, the variation cited above in desaturase index measures offer clear
evidence that genetic differences exist in the gene expression and/or activity kinetics for
�9-desaturase.

Rumen

Mammary

c-9, c-12 C18:2

3. Prevent
isomerase
shift

t-10, c-12 CLA

1. Add C18
polyunsaturated
fatty acids

c-9, t-11 CLA

c-9, t-11 CLA

4. Enhance
� 9-desaturase

� 9-desaturase
t-10 C18:1

t-11 C18:1

C18:0

t-11 C18:1

2. Inhibit
trans C18:1
reductase

Figure 3. Strategies to increase CLA content of milk products. Adapted from M. Griinari
(unpublished).

TRANS-10, CIS-12 CLA AND MILK FAT SYNTHESIS
Commercial supplements of CLA cause a reduction in milk fat yield when
abomasally infused or fed as rumen-protected salts. As summarized by Baumgard et
al. (7), effects are specific for milk fat and generally there are little or no effects on the
yield of milk or other milk components. We also demonstrated that the reduction in milk
fat was specific for the trans-10, cis-12 isomer as cis-9, trans-11 CLA had no effect (19).
We recently completed a dose response study of the effects of trans-10, cis-12 CLA on
milk fat yield (20) and these results are presented in Figure 4 along with data points
from other more recent unpublished studies by our group. A hyperbolic dose curve is
apparent and it is clear that trans-10, cis-12 CLA is a very potent inhibitor of milk fat
synthesis. As little as 3.5 g/d (0.016% DMI) results in a 25% reduction in milk fat yield
(20). The mechanism by which trans-10, cis-12 CLA is able to reduce milk fat yield is of
interest. Our initial results indicated that this CLA isomer causes a reduction in gene
expression (mRNA abundance) for key enzymes involved several aspects of milk fat
synthesis including mammary uptake and transport of preformed fatty acids, de novo
fatty acid synthesis, desaturation of fatty acids needed for maintenance of milk fat
fluidity, and esterification of fatty acids into milk fat triglycerides (21). Further
investigations on the mechanisms and signaling systems is an active area of
investigation by our group and others.
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Figure 4. Effects on milk fat yield (percent decrease) from various doses of
abomasally infused trans-10, cis-12 CLA. Closed diamonds are from
Baumgard et al. (20), open triangle is from Baumgard et al. (19), and
open circles represent more recent results (Peterson et al., unpublished).
One interesting aspect of the CLA story is the relationship between the trans-10,
cis-12 CLA isomer and classical diet-induced milk fat depression (MFD). Dairy
producers have observed a reduction in milk fat yield with a number of different types of
diets and dietary conditions, and this has been an active area of research for over half a
century. Results to date were summarized at the last conference (22) but a more
extensive review has recently been published (23). We demonstrated that diet-induced
MFD coincides with an increase in milk fat content of trans-10, cis-12 CLA. Based on
this and the aforementioned results with CLA isomers, Bauman and Griinari (23)
postulated the “biohydrogenation theory” to explain MFD. This theory hypothesizes that
“under certain dietary conditions the pathways of rumen biohydrogenation are altered to
produce unique fatty acid intermediates which are potent inhibitors of milk fat synthesis”
(23). trans-10, cis-12 CLA represents one example of such an intermediate, but it
seems likely that other unique fatty acid intermediates formed during rumen
biohydrogenation might also be inhibitory. For example, by analogy to the formation of
trans-10, cis-12 CLA from linoleic acid, we would expect the trans-10, cis-12, cis-15
C18:3 isomer formed from linolenic acid could also be a potent inhibitor of milk fat
synthesis (23). As the “biohydrogenation theory” is investigated and extended by
others, it will be interesting to see if it represents a unifying theory that explains the
basis for MFD across all diets.
In addition to implications related to understanding diet-induced MFD, there are a
number of situations where it might be of commercial value to consider reducing milk fat
yield. Over the last decade the price paid to producers for milk components has shifted
with a decrease in the value of milk fat and an increase in the value of milk protein.
Thus, any use of CLA to reduce milk fat yield would need to be considered in terms of
the economic benefit to producers. One situation of interest relates to producers
regulated by a quota system based on milk fat; dairy farmers in Canada and EU are
examples. We have just completed a longer-term study in which pregnant, well-fed
cows received rumen-protected CLA over the last 20 weeks of lactation (24). We
observed a 23% decrease in milk fat yield with no change in the yield of milk or milk
protein; cow health and well-being were unaffected (Table 3). Another circumstance

where a reduction in milk fat yield would be of possible interest is in the transition cow
(25) and this will be discussed in Dr. Overton’s presentation. Other situations are where
nutrients are limiting either due to feedstuff availability (e.g. summer pasture),
physiological state (early lactation) or environmental factors (e.g. heat stress). All of
these are areas of active research where the potential benefits include performance and
animal health and well-being; the first longer term results from feeding rumen-protected
CLA have been presented as abstracts. Medeiros et al. (26) demonstrated the energy
limitation response when they observed that rotationally grazed cows receiving rumenprotected CLA had reduced milk fat whereas milk protein yield was increased by 13%.
Likewise, a benefit by overcoming an energy limitation in early lactation was observed
when feeding rumen-protected CLA resulted in an increase in milk yield corresponding
to the reduction in milk fat (27).
Table 3. Performance of pregnant dairy cows treated with rumen-protected CLA
over the last 20 weeks of lactationa.
Variable
Control (n=12)
CLA (n=11)
SE
P-value
DMI, kg/d
22.8
22.6
0.5
0.78
Milk, kg/d
30.4
30.8
1.3
0.85
Fat
%
3.8
2.9
0.1
<0.001
Yield, g/d
1201
927
35
<0.001
Protein
%
3.1
3.2
0.1
0.61
Yield, g/d
992
1004
26
0.73
BCS
3.4
3.4
0.1
0.72
BW, kg
655
652
6
0.70
Net EB, Mcal/d
4.6
5.8
1.3
0.53
a
Cows received rumen-protected CLA (42.8 g/d of CLA) or EnerG II (Control). Adapted
from Perfield II et al. (24).

CONCLUSION
CLA are micronutrients found in food products derived from ruminants that have
many potential beneficial health effects. Two CLA isomers are of particular interest, cis
9, trans-11 because of its anticancer effects and trans-10, cis-12 because of its ability to
inhibit fat synthesis. Substantial animal variation exists in milk fat content of cis-9,
trans-11 CLA, and potential strategies to enhance levels of this isomer are detailed.
The trans-10, cis-12 CLA isomer is a potent inhibitor of fat synthesis and recent studies
have characterized dose-response relationships and effects of rumen-protected CLA on
milk fat yield. These results demonstrate that dietary supplements of CLA have the
potential to be utilized as a management tool to regulate milk lipid secretion, enhance
productivity and improve animal well-being.
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